Outperformed Approved Pan-HDAC Inhibitor Givinostat in Improving Muscle Function and Correcting Drivers of DMD Cardiomyopathy New Data Confirm TN-301’s Differentiated Mechanism and Opportunities to ...

Deramiocel has the potential to become the first therapy to address both skeletal and cardiac manifestations of Duchenne ...

The MarketWatch News Department was not involved in the creation of this content. -- NMD Pharma will also present an update on the ongoing SYNAPSE-MG Phase 2b clinical trial of ignaseclant in ...

New Indian clinical guidelines warn that age-related muscle loss, or sarcopenia, is an under-recognised health risk affecting ...

VALENCIA, Spain, March 11, 2026 /PRNewswire/ — ARTHEx Biotech, a clinical-stage biotechnology company advancing RNA-based therapeutics for neuromuscular disorders, today announced that the U.S. Food ...

Vyana Care offers personalized, evidence-based physiotherapy and digital rehabilitation, helping patients like Reema Sinha avoid surgery through movement-focused, root-cause treatments.

Interim observations from the Phase 2 TRAILHEAD study show continued improvement in handgrip strength, overall stability of elbow and shoulder strength in new dynamometry measurements Greater ...

Precision BioSciences Inc. (NASDAQ:DTIL) presented new preclinical findings for its PBGENE-DMD gene therapy at the Muscular ...

"As we prepare to commence the Phase1/2 FUNCTION-DMD clinical trial for PBGENE-DMD, we're excited to present new preclinical data highlighting its potential to deliver durable, long-term functional ...

New research suggests GLP-1 drugs may increase the risk of bone and tendon injuries and other conditions, including ...

Alzheimer's disease (AD) is a devastating cause of memory loss and cognitive decline, for which no curative treatment is available. Among lifestyle factors, physical activity stands out as possibly ...

As a physician who prescribes GLP-1 medications like Ozempic, Wegovy, semaglutide, and tirzepatide, I explain why increasing ...